News from Kitos
Cell proliferation assays are performed by four decades in cancer research to test the anti-proliferative activity of natural products and synthetic compounds in in vitro tumor models such as cell lines. However, current parameters used to quantify growth inhibition lead to a misinterpretation of results based on the exponential, and not linear, proliferation of cells in culture. We recently published in Journal of Cellular Physiology the development and experimental validation of a new parameter for the analysis of growth inhibition in proliferation assays, termed relative doubling capacity, that can be used to properly quantify the anti-proliferative activity of tested compounds in cell cultures and compare drug efficacy between distinct cell models.
Click here to download full-text and supplementary informations
Your comment will be posted after it is approved.
Leave a Reply.